Cencora, Inc. (NYSE:COR) COO Sells $13,532,720.76 in Stock

Cencora, Inc. (NYSE:COR) COO Robert P. Mauch sold 57,564 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the sale, the chief operating officer now directly owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Cencora Stock Performance

COR opened at $239.13 on Friday. The firm has a market capitalization of $47.70 billion, a P/E ratio of 26.05, a price-to-earnings-growth ratio of 1.82 and a beta of 0.45. The stock’s 50 day moving average price is $237.67 and its two-hundred day moving average price is $215.04. The company has a quick ratio of 0.52, a current ratio of 0.88 and a debt-to-equity ratio of 3.94. Cencora, Inc. has a 12-month low of $163.37 and a 12-month high of $246.75.

Cencora (NYSE:COR) last released its earnings results on Wednesday, January 31st. The company reported $3.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.86 by $0.42. The firm had revenue of $72.25 billion for the quarter, compared to analyst estimates of $68.81 billion. Cencora had a return on equity of 323.23% and a net margin of 0.69%. During the same quarter last year, the firm posted $2.71 EPS. On average, equities analysts forecast that Cencora, Inc. will post 13.43 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 26th. Shareholders of record on Friday, February 9th were issued a $0.51 dividend. The ex-dividend date of this dividend was Thursday, February 8th. This represents a $2.04 dividend on an annualized basis and a yield of 0.85%. This is a positive change from Cencora’s previous quarterly dividend of $0.24. Cencora’s dividend payout ratio (DPR) is 22.22%.

Institutional Trading of Cencora

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rise Advisors LLC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $25,000. Harbour Investments Inc. grew its holdings in shares of Cencora by 61.8% during the 1st quarter. Harbour Investments Inc. now owns 165 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares in the last quarter. CVA Family Office LLC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $34,000. MBM Wealth Consultants LLC acquired a new stake in shares of Cencora during the 4th quarter worth approximately $41,000. Finally, KB Financial Partners LLC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $42,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on COR. Barclays began coverage on Cencora in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $242.00 price target for the company. Leerink Partnrs reissued an “outperform” rating on shares of Cencora in a report on Monday, February 26th. SVB Leerink assumed coverage on Cencora in a report on Monday, February 26th. They set an “outperform” rating and a $261.00 price objective on the stock. Mizuho increased their price objective on Cencora from $192.00 to $224.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Finally, StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $218.22.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.